Lipocine Inc. (LPCN)

Lipocine Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	4.77	3.15	2.95	24.22	14.73
Short-Term Investments	17.26	29.38	41.67	0.45	4.34
Cash & Cash Equivalents	22.04	32.53	44.62	24.67	19.07
Cash Growth	-32.26%	-27.09%	80.88%	29.36%	-5.84%
Other Current Assets	0.83	1.61	1.76	0.66	0.56
Total Current Assets	22.86	34.14	46.38	25.33	19.63
Property, Plant & Equipment	0.12	0.13	0.01	0	0
Long-Term Investments	0	0	2.02	0	0
Other Long-Term Assets	0.02	3.28	4.07	0.02	0.02
Total Long-Term Assets	0.14	3.41	6.1	0.02	0.03
Total Assets	23	37.54	52.48	25.35	19.66
Accounts Payable	1.4	0.6	1.29	1.6	1.18
Current Debt	0	0	2.31	3.33	3.33
Other Current Liabilities	1.24	1.08	2.02	1.65	0.45
Total Current Liabilities	2.63	1.68	5.62	6.58	4.96
Long-Term Debt	0	0	0	2.26	3.81
Other Long-Term Liabilities	0	0.23	1.3	1.17	4.59
Total Long-Term Liabilities	0	0.23	1.3	3.43	8.41
Total Liabilities	2.63	1.91	6.91	10.01	13.37
Total Debt	0	0	2.31	5.59	7.15
Debt Growth	-	-	-58.66%	-21.79%	-30.33%
Retained Earnings	-199.78	-183.43	-172.67	-172.03	-151.07
Comprehensive Income	0.01	-0.02	-0.02	0	-0
Shareholders' Equity	20.37	35.63	45.57	15.34	6.29
Net Cash / Debt	22.04	32.53	42.31	19.08	11.92
Net Cash / Debt Growth	-32.26%	-23.11%	121.77%	60.03%	19.32%
Net Cash Per Share	4.18	6.19	8.21	5.82	7.83
Working Capital	20.23	32.46	40.76	18.75	14.67
Book Value Per Share	3.87	6.81	8.91	4.68	4.13

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).